Comparison of N-Terminal Pro–B-Natriuretic Peptide, C-Reactive Protein, and Creatinine Clearance for Prognosis in Patients With Known Coronary Heart Disease
Open Access
- 11 December 2006
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 166 (22) , 2455-2460
- https://doi.org/10.1001/archinte.166.22.2455
Abstract
Background The purpose of this study was to investigate the prognostic role of N-terminal pro–B-natriuretic peptide (NT-proBNP) serum level compared with C-reactive protein (CRP) level and creatinine clearance (CrCl) for the subsequent risk of cardiovascular events in a large cohort of patients with stable coronary heart disease (CHD). Methods Serum concentrations of NT-proBNP and CRP and CrCl were measured at baseline in a cohort of 1051 patients aged 30 to 70 years with CHD. The Cox proportional hazards model was used to determine the prognostic value of NT-proBNP, CRP, and CrCl on a combined cardiovascular disease (CVD) end point (fatal and nonfatal myocardial infarction and stroke). Results During follow-up (mean of 48.7 months), 95 patients (9.0%) experienced a secondary CVD event. Patients in the top quartile of the NT-proBNP distribution at baseline had a hazard ratio (HR) of 3.34 (95% confidence interval [CI], 1.74-6.45) for subsequent secondary CVD events compared with those in the bottom quartile (P for trend <.001) after controlling for age, sex, smoking status, history of diabetes mellitus, initial management of CHD, rehabilitation clinic, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and treatment with lipid-lowering drugs. For CRP, the corresponding HR was 1.76 (95% CI, 0.96-3.24) (P value for trend, .06). Patients with CrCl levels lower than 60 mL/min had an HR of 2.39 (95% CI, 1.06-5.40) compared with patients with a CrCl of 90 mL/min or higher (P for trend, .002). If all 3 markers were included simultaneously in 1 model, NT-proBNP still showed predictive ability for recurrent CVD events. Conclusion N-terminal proBNP may be a clinically useful marker weeks after an acute coronary event and may provide complementary prognostic information to established risk determinants.This publication has 24 references indexed in Scilit:
- Prognostic Value of Serial B-Type Natriuretic Peptide Testing During Follow-up of Patients With Unstable Coronary Artery DiseaseJAMA, 2005
- N-Terminal Pro–B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart DiseaseNew England Journal of Medicine, 2005
- Natriuretic peptides in unstable coronary artery diseasePublished by Oxford University Press (OUP) ,2004
- Kidney Disease as a Risk Factor for Development of Cardiovascular DiseaseCirculation, 2003
- High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart diseaseCurrent Opinion in Cardiology, 2002
- Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populationsBMJ, 2002
- The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2001
- Mortality by cause for eight regions of the world: Global Burden of Disease StudyPublished by Elsevier ,1997
- Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction.Circulation, 1993
- Augmented secretion of brain natriuretic peptide in acute myocardial infarctionBiochemical and Biophysical Research Communications, 1991